A revolutionary personalized cancer vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology is expected to receive regulatory approval by August, potentially allowing treatments to commence as early as September, according to the institute’s director, Alexander Gintsburg. This breakthrough marks a significant milestone in the global fight against cancer, leveraging advanced mRNA technology and artificial intelligence to tailor treatments for individual patients.

The Gamaleya Research Institute, renowned for its development of Sputnik V-the world’s first registered Covid-19 vaccine-has adapted mRNA technology, initially employed for combating infectious diseases, to the realm of oncology. In an interview with RIA Novosti, Alexander Gintsburg outlined the ambitious roadmap for the vaccine’s approval and implementation, stating, “We will likely receive permission at the end of August so that we can begin treating people in September.”

This groundbreaking cancer vaccine, unlike traditional immunotherapies, is a therapeutic option designed for patients already diagnosed with cancer. It works by activating the body’s immune system to target and destroy malignant cells. Cytotoxic lymphocytes, also known as white blood cells, play a central role in this process. Once vaccinated, the patient’s immune system is trained to recognize specific proteins (antigens) on the surface of tumor cells. This recognition enables the lymphocytes to identify and eliminate foreign, metastasizing cells throughout the body.

One of the most innovative aspects of this vaccine is its reliance on artificial intelligence (AI) to create a customized treatment for each patient. The AI analyzes the........

© Blitz